GT200900096A - Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada - Google Patents

Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Info

Publication number
GT200900096A
GT200900096A GT200900096A GT200900096A GT200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A GT 200900096 A GT200900096 A GT 200900096A
Authority
GT
Guatemala
Prior art keywords
dosage forms
chlorhydrate
palonosetron
improved stability
biodisponibility
Prior art date
Application number
GT200900096A
Other languages
English (en)
Inventor
Daniele Bonadeo
Giorgio Calderari
Enrico Braglia
Ricardo Braglia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38921772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT200900096(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GT200900096A publication Critical patent/GT200900096A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/473Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005Wall or coating material
    • A61K9/5021Organic macromolecular compounds
    • A61K9/5052Proteins, e.g. albumin
    • A61K9/5057Gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

EL PRESENTE INVENTO SE REFIERE A FORMAS DE DOSIFICACIÓN ORALES SÓLIDAS DEL CLORHIDRATO DE PALONOSETRON, LOS MÉTODOS PARA USAR LAS FORMAS DE DOSIFICACIÓN PARA TRATAR EL VÓMITO, Y LOS MÉTODOS PARA HACER LAS FORMAS DE DOSIFICACIÓN. LAS FORMAS DE DOSIFICACIÓN HAN MEJORADO LA ESTABILIDAD Y BIODISPONIBILIDAD, Y ESTÁN PREFERIBLEMENTE BAJO LA FORMA DE CÁPSULAS RELLENAS DE LÍQUIDO.
GT200900096A 2006-10-24 2009-04-23 Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada GT200900096A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85434206P 2006-10-24 2006-10-24

Publications (1)

Publication Number Publication Date
GT200900096A true GT200900096A (es) 2011-08-29

Family

ID=38921772

Family Applications (1)

Application Number Title Priority Date Filing Date
GT200900096A GT200900096A (es) 2006-10-24 2009-04-23 Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada

Country Status (36)

Country Link
US (2) US20080152704A1 (es)
EP (1) EP1940366B9 (es)
JP (1) JP5144527B2 (es)
KR (1) KR101441459B1 (es)
CN (1) CN101573106B (es)
AR (1) AR063362A1 (es)
AT (1) ATE427742T1 (es)
AU (1) AU2007308378B2 (es)
BR (1) BRPI0718497B1 (es)
CA (1) CA2666512C (es)
CL (1) CL2007003055A1 (es)
CO (1) CO6160289A2 (es)
CR (1) CR10728A (es)
CY (1) CY1109914T1 (es)
DE (1) DE602007000856D1 (es)
DK (1) DK1940366T3 (es)
EA (1) EA016455B1 (es)
ES (1) ES2325339T3 (es)
GT (1) GT200900096A (es)
HK (1) HK1117769A1 (es)
HN (1) HN2009000785A (es)
HR (1) HRP20090341T1 (es)
IL (1) IL198225A (es)
ME (1) ME01949B (es)
MX (1) MX2009004461A (es)
NO (1) NO342353B1 (es)
NZ (1) NZ576237A (es)
PL (1) PL1940366T3 (es)
PT (1) PT1940366E (es)
RS (1) RS50842B (es)
SI (1) SI1940366T1 (es)
SV (1) SV2009003238A (es)
TW (1) TWI367212B (es)
UA (1) UA97653C2 (es)
WO (1) WO2008049552A1 (es)
ZA (1) ZA200902773B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090082A2 (en) * 2006-01-27 2007-08-09 Eurand, Inc. Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
KR20140088230A (ko) * 2006-01-27 2014-07-09 앱탈리스 파마테크, 인코포레이티드 약 염기성 약물과 유기산을 포함하는 약물 전달 시스템
WO2010077669A2 (en) 2008-12-08 2010-07-08 Teva Pharmaceutical Industries Ltd. Palonosetron formulation
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
CN102048705B (zh) * 2009-11-10 2012-07-18 齐鲁制药有限公司 盐酸帕洛诺司琼口腔崩解片制剂及其制备方法
US20120253046A1 (en) * 2009-11-13 2012-10-04 Helsinn Healthcare S.A. Palonosetron metabolites
EP2722045B1 (en) 2009-11-18 2016-07-06 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
EP2361090B1 (en) * 2009-11-18 2014-05-21 Helsinn Healthcare SA Compositions for treating centrally mediated nausea and vomiting
CN106974912A (zh) 2011-10-18 2017-07-25 赫尔辛医疗股份公司 奈妥匹坦和帕洛诺司琼的治疗性组合
CN107137374B (zh) * 2012-06-02 2020-04-07 正大天晴药业集团股份有限公司 帕洛诺司琼的固体药物组合物
WO2014147096A1 (en) * 2013-03-19 2014-09-25 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
CA2919892C (en) 2013-08-12 2019-06-18 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3087987A4 (en) * 2013-12-23 2017-08-02 Samyang Biopharmaceuticals Corporation Pharmaceutical composition containing palonosetron
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016064873A1 (en) * 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
KR20160128573A (ko) * 2015-04-29 2016-11-08 주식회사 삼양바이오팜 약제학적 패키지
JP2019019067A (ja) * 2017-07-13 2019-02-07 ニプロ株式会社 液体製剤
CN111205283A (zh) * 2020-01-20 2020-05-29 广州九植医药科技有限公司 一种盐酸帕洛诺司琼有关物质b的合成方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1015251A (en) * 1963-03-12 1965-12-31 Glaxo Lab Ltd Aqueous pharmaceutical compositions in capsule form
US4182914A (en) * 1974-01-22 1980-01-08 Nippon Oil Company Limited Process for continuously producing diisopropyl ether
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
US4937247A (en) * 1985-04-27 1990-06-26 Beecham Group P.L.C. 1-acyl indazoles
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5240954A (en) * 1985-06-25 1993-08-31 Glaxo Group Limited Medicaments
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
US4906755A (en) * 1986-11-03 1990-03-06 Merrell Dow Pharmaceuticals Inc. Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds
US5011846A (en) * 1988-02-23 1991-04-30 Merrell Dow Pharmaceuticals Inc. Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron
GB8914804D0 (en) * 1989-06-28 1989-08-16 Glaxo Group Ltd Process
KR970007917B1 (ko) * 1989-11-28 1997-05-17 신텍스 인크. 신규 삼환식 화합물
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US20040136914A1 (en) * 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20030095926A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US6294548B1 (en) * 1998-05-04 2001-09-25 Hoffmann-La Roche Inc. Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride
FR2818905A1 (fr) * 2000-12-28 2002-07-05 Cll Pharma Compositions pharmaceutiques colloidales micellaires renfermant un principe actif lipophile
FR2823118B1 (fr) * 2001-04-04 2004-03-19 Lavipharm Lab Inc Nouvelle composition filmogene a usage topique et son utilisation pour la delivrance d'agents actifs
FR2827770B1 (fr) * 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
IL159729A0 (en) * 2004-01-06 2004-06-20 Doron I Friedman Non-aqueous composition for oral delivery of insoluble bioactive agents

Also Published As

Publication number Publication date
CA2666512A1 (en) 2008-05-02
ME01949B (me) 2010-08-31
PT1940366E (pt) 2009-06-17
RS50842B (sr) 2010-08-31
EP1940366B1 (en) 2009-04-08
TW200827355A (en) 2008-07-01
AR063362A1 (es) 2009-01-21
AU2007308378B2 (en) 2013-02-21
PL1940366T3 (pl) 2009-09-30
NO342353B1 (no) 2018-05-07
DK1940366T3 (da) 2009-06-29
KR101441459B1 (ko) 2014-09-18
CY1109914T1 (el) 2014-09-10
AU2007308378A1 (en) 2008-05-02
TWI367212B (en) 2012-07-01
NZ576237A (en) 2011-12-22
CO6160289A2 (es) 2010-05-20
CL2007003055A1 (es) 2008-03-24
DE602007000856D1 (de) 2009-05-20
BRPI0718497A2 (pt) 2014-07-08
ATE427742T1 (de) 2009-04-15
MX2009004461A (es) 2009-09-16
EA200970396A1 (ru) 2009-10-30
IL198225A (en) 2013-03-24
ZA200902773B (en) 2010-03-31
CN101573106B (zh) 2013-07-24
UA97653C2 (ru) 2012-03-12
US20080152704A1 (en) 2008-06-26
US20170035748A1 (en) 2017-02-09
SV2009003238A (es) 2009-11-09
HK1117769A1 (en) 2009-01-23
WO2008049552A1 (en) 2008-05-02
ES2325339T3 (es) 2009-09-01
JP2009507933A (ja) 2009-02-26
CA2666512C (en) 2014-05-27
EP1940366B9 (en) 2009-12-02
BRPI0718497B1 (pt) 2024-02-06
HN2009000785A (es) 2011-10-14
HRP20090341T1 (en) 2009-07-31
JP5144527B2 (ja) 2013-02-13
CN101573106A (zh) 2009-11-04
EP1940366A1 (en) 2008-07-09
SI1940366T1 (sl) 2009-08-31
EA016455B1 (ru) 2012-05-30
KR20090073234A (ko) 2009-07-02
NO20091945L (no) 2009-05-25
CR10728A (es) 2009-07-23
IL198225A0 (en) 2009-12-24

Similar Documents

Publication Publication Date Title
GT200900096A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
HK1247822A1 (zh) 用於活性劑口服給藥的製劑
UY33017A (es) Tratamiento para trastornos gastrointestinales
DK2099406T3 (da) Opbevarings- og udleveringsindretninger til administration af oralt transmucosale doseringsformer
BRPI1012831A2 (pt) forma de dosagem farmacêutica para administração oral de um inibidor da família bcl-2.
CR11285A (es) Composicion farmaceutica que contiene un antagonista del canal de calcio de tipo dihipropiridina y metodo para la prepacion de la misma
MX343689B (es) Formulaciones combinadas de darunavir.
PT3402488T (pt) Formas de dosagem orais sólidas de eslicarbazepina
MX341976B (es) Formulaciones de darunavir.
HK1248544A1 (zh) 穩定的口服給藥用藥物組合物
CO6300935A2 (es) Formulaciones orales e inyectables de compuestos de tetraciclina
HUE049298T2 (hu) Szitagliptin tartalmú stabil gyógyszerészeti készítmények azonnali hatóanyag leadású tabletta formájában
AR070392A1 (es) Composiciones de tabletas de ranitidina de desintegracion oral y sus metodos de eleboracion
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
AR068368A1 (es) Formas solidas de dosificacion de azitromicina de liberacion controlada
CO7111279A2 (es) Composiciones farmacéuticas orales estables de liberación inmediata que contienen prasugrel
MX2016006087A (es) Formulaciones de desintegracion rapida y metodos de uso.
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
IT1399492B1 (it) Composizioni farmaceutiche effervescenti contenenti n-acetilcisteina.
AR084435A1 (es) Combinacion y composicion para el tratamiento de obesidad
DOP2009000091A (es) Formas de dosificación de clorhidrato de palonosetron que tienen estabilidad y biodisponibilidad mejorada
MX2016013711A (es) Antagonistas de receptores de glumato metabotropicos 2/3 (mglu2/3) para el tratamiento de varias discapacidades intelectuales.
ZA201804275B (en) Oral pharmaceutical composition comprising taste-masked n-acetylcysteine